Title: Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction.
Authors: Volpe, Massimo; Galiuto, Leonarda
Abstract: The FINEARTS-HF trial evaluated the efficacy and safety of finerenone, a non-steroidal mineralocorticoid receptor antagonist, in patients with heart failure and mildly reduced or preserved ejection fraction. The trial showed that finerenone significantly reduced total worsening heart failure events and cardiovascular death compared to a placebo. While finerenone improved patient-reported symptom scores, it did not show a significant difference in kidney outcomes or New York Heart Association functional class improvement. The study highlighted the potential benefits of finerenone in managing heart failure, particularly in reducing worsening heart failure events.
Subjects: DISEASE risk factors; HEART failure patients; ANGIOTENSIN-receptor blockers; ACE inhibitors; SYSTOLIC blood pressure
Publication: European Heart Journal, 2025, Vol 46, Issue 1, p103
ISSN: 0195-668X
Publication type: Academic Journal
DOI: 10.1093/eurheartj/ehae679

Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction.

Volpe, Massimo; Galiuto, Leonarda